Categories: HealthcareNews

NKGen Biotech to Present at the Cantor Fitzgerald Global Healthcare Conference 2023

SANTA ANA, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) — NKGen Biotech, Inc. (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK natural killer (“NK”) cell therapies, today announced that its Executive Leadership will present at the Cantor Fitzgerald 2023 Global Healthcare Conference on Wednesday, September 27, 2023, in New York City. Please see details below:

Cantor Fitzgerald Global Healthcare Conference
Format: Company presentation
Date: Wednesday, September 27, 2023
Time: 4:45 pm ET
Location: New York, NY

The webcast will be accessible on the Events & Presentations page in the Investors section of the Company’s website at www.nkgenbiotech.com beginning on the day of the event.

About NKGen
NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK NK cell therapies. NKGen is headquartered in Santa Ana, California, USA. For more information, please visit www.nkgenbiotech.com.

Internal Contact:
Denise Chua, MBA, CLS, MT (ASCP)
Vice President, Investor Relations and Corporate Communications
NKGen Biotech, Inc.
949-396-6830
dchua@nkgenbiotech.com

External Contacts:
Chris Calabrese
Managing Director
LifeSci Advisors, LLC
ccalabrese@lifesciadvisors.com

Kevin Gardner
Managing Director
LifeSci Advisors, LLC
kgardner@lifesciadvisors.com

Staff

Recent Posts

Interactive Strength Inc. (Nasdaq: TRNR) Issues Year-End Update, Looks Ahead to 2025

AUSTIN, TEXAS / ACCESSWIRE / December 23, 2024 / Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or…

16 minutes ago

Quest Diagnostics Upholds Strong Governance and Ethics With Robust Oversight, ESG Integration, and Comprehensive Risk Management

Originally published in Quest Diagnostics' 2023 Corporate Responsibility ReportNORTHAMPTON, MA / ACCESSWIRE / December 23,…

16 minutes ago

Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Marlborough, Massachusetts--(Newsfile Corp. - December 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage…

1 hour ago

ILiAD Biotechnologies Announces the Passing of Chief Operating Officer Ken Solovay

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…

3 hours ago

ILiAD Biotechnologies Announces the Passing of Chief Operating Officer Ken Solovay

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…

3 hours ago

Hallmark Adds Senior Executives to Enhance Customer Success and Strategic Partnerships

New leadership roles highlight Hallmark’s unique vendor-neutral approach to helping health systems build flexible, efficient,…

3 hours ago